Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biocryst Pharmaceuticals

7.83
+0.03000.38%
Post-market: 7.830.00000.00%19:24 EDT
Volume:1.29M
Turnover:10.08M
Market Cap:1.64B
PE:-18.21
High:7.88
Open:7.83
Low:7.75
Close:7.80
Loading ...

Institutional investors control 75% of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and were rewarded last week after stock increased 4.9%

Simply Wall St.
·
19 Mar

The 4.9% return this week takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) shareholders five-year gains to 295%

Simply Wall St.
·
18 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney

Reuters
·
12 Mar

BUZZ-BioCryst takes legal action to defend rare genetic drug patent; shares fall

Reuters
·
11 Mar

BioCryst reports inducement grants under Nasdaq listing rule

TIPRANKS
·
06 Mar

BRIEF-Biocryst Pharmaceuticals Says CFO Anthony Doyle To Resign Effective April 9, 2025

Reuters
·
04 Mar

BioCryst Pharmaceuticals CFO Anthony Doyle to Step Down

MT Newswires Live
·
04 Mar

BioCryst CFO Anthony Doyle to resign, effective April 9

TIPRANKS
·
04 Mar

BioCryst Pharmaceuticals Inc - CFO Anthony Doyle to Resign Effective April 9, 2025

THOMSON REUTERS
·
04 Mar

BioCryst Pharmaceuticals Price Target Maintained With a $18.00/Share by Citizens Capital Markets

Dow Jones
·
03 Mar

Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and BioCryst (BCRX)

TIPRANKS
·
03 Mar

Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?

Insider Monkey
·
01 Mar

BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Zacks
·
27 Feb

Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher

Zacks
·
26 Feb

Analysts Are Updating Their BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Estimates After Its Yearly Results

Simply Wall St.
·
26 Feb

Evercore ISI Sticks to Their Buy Rating for BioCryst (BCRX)

TIPRANKS
·
26 Feb